Drug intelligence / Profile preview

KI-3149

Development stage: Preclinical
Lead developer: Kuhnil Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

KI-3149 is a small molecule drug candidate currently in the research phase, developed by Kuhnil Pharmaceuticals. It is primarily being investigated for the treatment of Acute Myeloid Leukemia (AML) and is also listed in development pipelines for Renal Cell Carcinoma (RCC). As a part of Kuhnil's oncology research program, KI-3149 represents an effort to develop targeted small molecule inhibitors for high-need hematologic and solid tumor indications. The specific molecular target and mechanism of action have not been publicly detailed by the developer.

Beyond the preview

Go deeper on KI-3149.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KI-3149.

Explore the full profile